HIV-1 Subtype C Gag-Specific T-Cell Responses in Relation to Human Leukocyte Antigens in a Diverse Population of HIV-Infected Ethiopians Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Knowledge of the most dominant T-cell epitopes in the context of the local human leukocyte antigen (HLA) background is a prerequisite for the development of an effective HIV vaccine. In 100 Ethiopian subjects, 16 different HLA-A, 23 HLA-B, and 12 HLA-C specificities were observed. Ninety-four percent of the population carried at least 1 of the 5 most common HLA-A and/or HLA-B specificities. HIV-specific T-cell responses were measured in 48 HIV-infected Ethiopian subjects representing a wide range of ethnicities in Ethiopia using the interferon (IFN)-gamma enzyme-linked immunospot (Elispot) assay and 49 clade C-specific synthetic Gag peptides. Fifty-eight percent of the HIV-positive study subjects showed T-cell responses directed to 1 or more HIV Gag peptides. Most Gag-specific responses were directed against the subset of peptides spanning Gag p24. The breadth of response ranged from 1 to 9 peptides, with most (78%) individuals showing detectable responses to <3 Gag peptides. The magnitude of HIV-specific T-cell responses was not associated with HIV viral load but correlated positively with CD4 T-cell counts. The most frequently targeted Gag peptides overlapped with those previously described for HIV-1 subtype C-infected southern Africans, and therefore can be used in a multiethnic vaccine.

authors

  • Tsegaye, Aster
  • Ran, Leonie
  • Wolday, Dawit
  • Petros, Beyene
  • Dorigo, Wendelien
  • Piriou, Erwan
  • Messele, Tsehaynesh
  • Sanders, Eduard
  • Tilahun, Tesfaye
  • Eshetu, Deresse
  • Schuitemaker, Hanneke
  • Coutinho, Roel A
  • Miedema, Frank
  • Borghans, José
  • Baarle, Debbie van

publication date

  • August 1, 2007